口服托法替尼有效治疗类血管病

IF 0.6 Q3 MEDICINE, GENERAL & INTERNAL

Clinical Case Reports Pub Date : 2025-05-28 DOI:10.1002/ccr3.70536

Parvin Mansouri, Nikoo Mozafari

引用次数: 0

摘要

我们报告了一位患有严重难治性类活体血管病变的女性，她成功地接受了托法替尼治疗（5mg，每天两次）。溃疡在2-3个月的时间内逐渐愈合，在1年的随访期间没有发生任何不良事件。托法替尼可能被认为是一种安全有效的治疗类活体血管病变的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib

查看原文本刊更多论文

Effective Treatment of Livedoid Vasculopathy With Oral Tofacitinib

We present a woman with severe refractory livedoid vasculopathy who was successfully treated with tofacitinib (5 mg twice a day). The ulcers gradually healed over a period of 2–3 months without experiencing any adverse events over a 1-year follow-up period. Tofacitinib may be considered a safe and effective therapy for patients with livedoid vasculopathy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Case Reports MEDICINE, GENERAL & INTERNAL-

自引率

14.30%

发文量

1268

审稿时长

13 weeks

期刊介绍： Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).